Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

FORCE · Imaging the Force of Cancer

H2020Status: CLOSED1 January 201631 July 2021EU funding €5,812,631Call H2020-PHC-2014-2015

Cancer is the second leading cause of mortality in EU member states with ~90% of all cancer deaths caused by metastatic spread. Despite its significance, measuring metastatic potential as well as potential indicators of therapy efficacy remain unmet clinical challenges. Recently, it has been demonstrated in vitro, that aggressive metastatic cells pull on their surroundings suggesting that metastatic potential could be gauged by measuring the forces exert by tumours. Furthermore, many solid tumours show a significantly increased interstitial fluid pressure (IFP) which prevents the efficient uptake of therapeutic agents. As a result, a reduction in IFP is recognized as a hallmark of therapeutic efficacy. Currently, there is no non-invasive modality that can directly image these forces in vivo.Our objective is the non-invasive measurement of both IFP within tumours as well as the forces they exert on their surrounding environment. This will be used to predict a tumour’s metastatic potential and importantly, changes in these forces will be used to predict the therapeutic efficacy of drug therapy. To attain this goal, the biomechanical properties of the tumour and its neighbouring tissue will be measured via MR-elastography at various measured deformation states. Resultant images will be used to reconstruct images of the internal and external forces acting on the tumour. We call this novel imaging modality Magnetic Resonance Force (MRF) imaging .We will calibrate MRF via cell cultures and pre-clinical models, and then test the method in breast, liver, and brain cancer patients. Thereby, we will investigate whether MRF data can predict metastatic spread and measure IFP in patients. We will also investigate the potential to non-invasively modulate the force environment of cancer cells via externally applied shear forces with the aim of impacting cell motility and proliferation. This can provide novel mechanism for anticancer therapeutic agents via mechanotransduction.

Consortium · 20 organisations

coordinator

KING'S COLLEGE LONDON

UK · €2,196,560

participant

INTEGRATED TECHNOLOGIES LIMITED

UK · €98,500

participant

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

FR · €343,100

participant

UNIVERSITAT BASEL

CH

participant

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

FR · €271,020

thirdParty

OSLO UNIVERSITETSSYKEHUS HF

NO

thirdParty

NEUROSCIENCE RESEARCH ASUTRALIA

AU

participant

UNIVERSITY OF NEW SOUTH WALES

AU

participant

UNIVERSITAET LEIPZIG

DE · €503,500

participant

SCREENCELL

FR · €322,500

participant

BRIGHAM INC

US · €49,375

participant

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH

CH

participant

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

DE · €515,000

participant

UNIVERSITETET I OSLO

NO · €731,000

thirdParty

UNIVERSITE PARIS CITE

FR

participant

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT

FR

participant

CERMAKOVA IVA

DE · €150,375

participant

PHILIPS MEDICAL SYSTEMS NEDERLAND BV

NL

participant

INSTITUTE OF CANCER RESEARCH: THE ROYAL CANCER HOSPITAL LBG

UK · €631,701

thirdParty

UNIVERSITATSSPITAL BASEL

CH

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.